Sign up to save your podcasts
Or
Share 2025 GTD Guidelines with Christianne Lok and Michael Seckl
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
2025 GTD Guidelines with Christianne Lok and Michael Seckl
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christianne Lok and Michael Seckl to discuss 2025 GTD Guidelines.
Christianne Lok is a leading expert in gynecologic oncology, renowned for her work on cancer diagnosis and treatment during pregnancy as part of the International Network on Cancer, Infertility and Pregnancy (INCIP). She plays a pivotal role in research and clinical guidelines for gestational trophoblastic disease, addressing both medical and psychosocial dimensions. Her contributions to ovarian cancer research include biomarker studies—particularly on ctDNA and HE4—as well as molecular profiling and biobanking of rare ovarian cancer subtypes. Lok actively participates in international collaborations such as ESGO, GCIG, ISSTD, ENGOT and EOTTD, shaping global standards in women’s cancer care. Her prolific publication record underscores her influence in advancing multidisciplinary, patient-centered research.
Michael Seckl is a Professor of Molecular Oncology at Imperial College London, where he leads research in lung cancer and trophoblastic disease. He earned his medical degree from UCL, completed oncology training, and obtained a PhD in signal transduction from the University of London. He directs the National Trophoblastic Disease and MOGCT Centre. An international leader in trophoblastic disease, he has held key roles in ISSTD, EOTTD, and EURACAN, and serves on multiple editorial and grant committees. His work is widely funded and recognized, earning him a Fellowship of the Academy of Medical Sciences (FMedSci) in 2017.
View all episodes
By ijgcgroupIn this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christianne Lok and Michael Seckl to discuss 2025 GTD Guidelines.
Christianne Lok is a leading expert in gynecologic oncology, renowned for her work on cancer diagnosis and treatment during pregnancy as part of the International Network on Cancer, Infertility and Pregnancy (INCIP). She plays a pivotal role in research and clinical guidelines for gestational trophoblastic disease, addressing both medical and psychosocial dimensions. Her contributions to ovarian cancer research include biomarker studies—particularly on ctDNA and HE4—as well as molecular profiling and biobanking of rare ovarian cancer subtypes. Lok actively participates in international collaborations such as ESGO, GCIG, ISSTD, ENGOT and EOTTD, shaping global standards in women’s cancer care. Her prolific publication record underscores her influence in advancing multidisciplinary, patient-centered research.
Michael Seckl is a Professor of Molecular Oncology at Imperial College London, where he leads research in lung cancer and trophoblastic disease. He earned his medical degree from UCL, completed oncology training, and obtained a PhD in signal transduction from the University of London. He directs the National Trophoblastic Disease and MOGCT Centre. An international leader in trophoblastic disease, he has held key roles in ISSTD, EOTTD, and EURACAN, and serves on multiple editorial and grant committees. His work is widely funded and recognized, earning him a Fellowship of the Academy of Medical Sciences (FMedSci) in 2017.